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Background: Pertussis (whooping cough) remains a public health problem despite extensive vaccination strategies.
Better understanding of the host-pathogen interaction and the detailed B. pertussis (Bp) target recognition pattern
will help in guided vaccine design. We characterized the specific epitope antigen recognition profiles of serum
antibodies (‘the reactome’) induced by whooping cough and B. pertussis (Bp) vaccines from a case–control study
conducted in 1996 in infants enrolled in a Bp vaccine trial in Sweden (Gustafsson, NEJM, 1996, 334, 349–355).
Methods: Sera from children with whooping cough, vaccinated with Diphtheria Tetanus Pertussis (DTP) whole-cell
(wc), acellular 5 (DPTa5), or with the 2 component (a2) vaccines and from infants receiving only DT (n = 10 for each
group) were tested with high-content peptide microarrays containing 17 Bp proteins displayed as linear (n = 3175)
peptide stretches. Slides were incubated with serum and peptide-IgG complexes detected with Cy5-labeled goat
anti-human IgG and analyzed using a GenePix 4000B microarray scanner, followed by statistical analysis, using PAM
(Prediction Analysis for Microarrays) and the identification of uniquely recognized peptide epitopes.
Results: 367/3,085 (11.9%) peptides were recognized in 10/10 sera from children with whooping cough, 239 (7.7%)
in DTPwc, 259 (8.4%) in DTPa5, 105 (3.4%) DTPa2, 179 (5.8%) in the DT groups. Recognition of strongly recognized
peptides was similar between whooping cough and DPTwc, but statistically different between whooping cough vs.
DTPa5 (p < 0.05), DTPa2 and DT (p < 0.001 vs. both) vaccines. 6/3,085 and 2/3,085 peptides were exclusively
recognized in (10/10) sera from children with whooping cough and DTPa2 vaccination, respectively. DTPwc resembles
more closely the whooping cough reactome as compared to acellular vaccines.
Conclusion: We could identify a unique recognition signature common for each vaccination group (10/10
children). Peptide microarray technology allows detection of subtle differences in epitope signature responses and
may help to guide rational vaccine development by the objective description of a clinically relevant immune
response that confers protection against infectious pathogens.
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Pertussis (whooping cough) caused by B. pertussis (Bp), re-
mains a major global public health problem [1,2]. Despite a
vaccine coverage over 90% in newborns, pertussis remains
endemic in the Western countries [3]. In the first months
of 2010, outbreaks have been described in Ireland [4], Israel
[5] and USA [6]. In California a new outbreak in 2014 was
particularly severe, with 10.831 reported cases from January
1st to December 31st [7] (the worst toll since 1947).
The efficacy of current vaccination programs is likely
hampered by adaptation of the pathogen, overcoming the
effect of herd immunity [8]. A comprehensive study cover-
ing Bp clinical isolates from 1935 to 2004 showed the
appearance of a Bp strain that carries a mutation in the
pertussis toxin promoter; the increased expression of this
virulence factor directly correlated with the resurgence of
pertussis in the last decades in the Netherlands [9]. Another
study from the same country, covering the period 1965 to
1992, showed the circulation of different serotypes of the
pathogen in correlation with the use of whole cell or acellu-
lar pertussis vaccines in different time-frames [9]. Substantial
evidence has been accumulated in the last two years that
immunity induced by acellular vaccines is much shorter
lived than immunity induced by whole cell vaccines [10].
There is an unmet need i) to depict the immunological
recognition matrix to understand the specific epitope recog-
nition pattern induced by natural infection with Bp, ii) to
identify differences in immune recognition induced by avail-
able Bp vaccines as compared to natural infection, and iii)
to objectively define the qualitative differences in humoral
target recognition induced by current vaccines [11]. We
assessed in the current study the immune recognition pat-
tern in serum from infants with whooping cough and in 3
groups of infants randomized to different Bp vaccines from
a trial conducted 1996 in Sweden [12] using a high-content
peptide microarray. The immune recognition profile (or
‘reactome’) represents a detailed molecular recognition
‘fingerprint’ of serum IgG directed against linear epitopes.
Material and Methods
Patient samples
Samples were randomly selected among the serum sam-
ples from the pertussis vaccine Stockholm trial I [12],
stored at the bio-bank of the Swedish National Institute
of Public Health. Samples from children born during
1992, collected at 14 study sites after the completion of
the vaccination (doses at 2, 4, and 6 months of age),
were included in the study according to the following
scheme as described in detail [12].
1. 10 children who received a diphtheria (D) and
tetanus (T), vaccine (DT, produced by Swedish
National Bacteriological Laboratory, Stockholm,
Sweden) as placebo, and developed whooping cough;;2. 10 children immunized with the diphtheria (D),
tetanus (T), pertussis (P) whole cell (wc) (DTPwc)
vaccine licensed in the United States (Connaught
Laboratories, Swiftwater, PA, USA);
3. 10 children immunized with the 5 component
acellular candidate DTPa5 vaccine (Connaught
Laboratories, Toronto, Canada);
4. 10 ichildren immunized with the 2 component
acellular candidate DTPa2 vaccine (SmithKline
Beecham, Rixensart, Belgium);
5. 10 children immunized with the Swedish-produced
DT vaccine and did not develop whooping cough.
Sera were collected 30 days after the last dose, except
for the group which whooping cough (group 1, convales-
cence sera).
Ethics statement
The Stockholm regional ethics committee North (Dnr
911258) has approved the study. All subjects provided
informed consent. Both parents of the children pro-
vided informed consent on their behalf. The informed
consent was provided in a written format, signed and is
on file at the Swedish National Institute of Public
Health, Stockholm, Sweden.
Microarray slides and experiments
Peptide microarray slides were customized and manufac-
tured by JPT (Berlin, Germany). The slides contain three
identical sub-arrays with 3,175 unique peptides on each
subarray. Each sub-array contains 16 blocks arranged in
a regular pattern, with spots arranged in a matrix 16 X
15. An image of a microarray is provided in the Add-
itional file 1: Figure S1 (Schematic microarray template)
and a table with the list of the peptides, Additional file
2: Table S1 (S1a, non-variant peptides, S1b, variant
peptides) are available in the online data supplement.
Each sub-array contains positive controls, negative con-
trols and the unique peptides spanning 17 Bp proteins
(Table 1), a total of 11,520 spots per slide. The entire
amino acid sequence of each Bp protein was printed on
the microarray, as 15-mer amino acid peptides overlap-
ping the previous and next printed peptides by 11 amino
acids; this allows to identify minimal amino acid epi-
topes of 4 amino acids per spot defined by antibody re-
activity. Variant peptides for the 17 Bp proteins, published
earlier [13], were also printed on the microarray (and are
listed in Additional file 2: Table S1, S1a, non-variant pep-
tides, S1b, variant peptides, in the supplementary online
material).
Experiments were performed following a standardized
protocol [14-16]: 300 μL serum diluted 1/100 in washing
solution (filtered PBS, 3% fetal calf serum, FCS, Lot nr
45K3397, Sigma, Munich Germany and 0.5% Tween)
Table 1 B. pertussis proteins spotted on the peptide microarray slides
Protein ID Accession nu Function Vaccine component
1 Pertussis toxin subunit 1 precursor, (ptxA) O69258 Toxin subunit All vaccines
2 Pertussis toxin subunit 2 precursor, (ptxB) P04978 Toxin subunit
3 Pertussis toxin subunit 3 precursor, (ptxC) P04979 Toxin subunit
4 Pertussis toxin subunit 4 precursor, (ptxD) P0A3R5 Toxin subunit
5 Pertussis toxin subunit 5 precursor, (ptxE) P04981 Toxin subunit
6 P.69 protein (pertactin/PRN) CAA09473 Adhesin DTPa5 & DTPwc
7 Filamentous hemagglutinin (FHA) AAA22974 Adhesin DTPA2,5 & DTPwc
8 Fim2 pilic subunit (Fim2) Q8VVA0 Adhesin DTPa5
9 Fim3 pilic subunit (Fim3) precursor CAA35920/P17835 Adhesin DTPa5& DTPwc
10 Tracheal colonization factor (TCF) CAA08832/O86135 Adhesin DTPwc
11 Bifunctional hemolysin-adenylate cyclase precursor (ATC/cyaA) P15318 toxin DTPwc
12 Outer membrane porin protein precursor (OMP) CAA41398, 1/Q04064 Outer membrane porin protein DTPwc
13 Outer membrane porin protein (OmpQ) CAD12825, Q8VV98 Outer membrane porin protein DTPwc
14 GTP-binding elongation factor (BipA) Q7VYR0 Regulatory protein DTPwc
15 Bordetella resistance to killing (BrkA) AAA51646 Putative adhesion DTPwc
16 Vag8 protein (autotransporter) (Vag8) CAD12828/Q8VV95 Autotransporter DTPwc
17 Putative autotransporter (BapC) AAC31207 Autotransporter DTPwc
B. pertussis proteins spotted on the peptide microarray slides used in the study. The list includes all the acellular vaccines components and other Bp virulence
factors. DTPwc: Diphtheria Tetanus Pertussis whole cell vaccine; DTPa5: Diphtheria Tetanus Pertussis 5 component vaccine; DTPa2: Diphtheria Tetanus Pertussis 2
component vaccine.
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with a cover slip (Gene-Frame, Abgene, UK) to evenly
distribute the dilution over the slide and incubated at
+4°C in a humid chamber for 16 hours; after the re-
moval of the cover slip, the slides were washed 5 times
on a shaker for 5 min each (twice with washing solution,
twice with sterile water and one wash with filtered Milli
Q water at the end).After washing, 300 μL Cy5-labeled
goat anti-human IgG, affinity purified secondary anti-
body (Abcam, UK) diluted 1/500 in the washing solution
were added (in the dark), and incubated in the dark 1 hour
in a humid chamber at room temperature. Washing steps
were repeated after the incubation with the secondary
antibody. Prior to scanning, slides were dried with a slid
spinner (Euro Tech, UK). Five additional slides were proc-
essed using only buffer in the first incubation step, to de-
tect false positive spots due to non-specific binding of the
secondary reagent. High-definition images from the slides
were acquired with GenePix 4000B microarray scanner
(Axon Instruments-Molecular Devices, Union City, US)
using the wavelength 635 nm (red channel, for the specific
IgG signal quantification) and 532 nm (green channel,
positive controls for grid alignment and orientation). Data
acquisition from the images was performed with the soft-
ware Gene Pix 6 Pro (Axon Instruments-Molecular
Devices, Union City, US).
Data analysis
Data analysis consisted of 4 steps as described [17].Quality control All images and aligned files were visu-
ally inspected to check for artifacts and for spots errone-
ously flagged by the software. Images of background and
foreground intensities were produced for every sub-array
by using bioinformatics tools. All spots or areas which
did not represent a high quality signal were removed
from analysis. Further quality controls were also per-
formed [17] and the intensity values were background-
corrected (index = Log2(foreground/background)).
False positive, “empty” spots removal and exclusion of
low intensity signal spots All spots showing a response
on the buffer slides - and for this reason identified as
possible false positive - were removed from the analysis,
as well as all spots that did not show any signal
(“empty”, with an index value ≤ −50) in the data acquisi-
tion process. Low response spots, with a signal below a
computed cut off (μ + 2SD, where SD is the standard
deviation of μ, the mean value of negative controls in
the slides of each study group) were also removed.
Normalization the normalization process was per-
formed using the simple linear model as described be-
fore [18,15,14,16,17]. The quality of the normalization
was assessed by inspection of the normalized data plot
in all the study groups.
Analysis and data mining Data analysis was performed
using two different statistical methods: (i) PAM (Prediction
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performs sample classification from peptide recognition
data providing a list of significant peptides whose response
level characterizes each diagnostic group. Compared to
other differential recognition analysis methods, PAM is
highly selective and allows the detailed examination of each
time point in case of consecutive serum testing. This
reveals only the peptide target with good predictive power
associated with the differentiation of the patient group(s).
This will result in a set of peptides constantly weakly recog-
nized in one group and strongly in the other group. (ii) ‘Ex-
clusive recognition analysis’ (ERA) of epitopes predicted by
PAM. The latter approach identifies epitopes recognized in
serum from individuals exclusively in one group but never
in serum from any individual in a control reference group,
e.g. in the current report the ‘reference’ individuals who re-
ceived placebo (termed ‘exclusively recognized epitopes’,
ERA). Strongly recognized peptides identified in each group
were plotted according to index value and number of times
they were recognized in the group of interest. Lastly, a 3D-
graphical representation of the “reactome” [20] of B. pertus-
sis proteins was computed for every group, by plotting
mean index value for every peptide, as well as the protein
and position on the respective amino acid-sequence of the
protein. A similar 3D-plot was computed to compare
the signals in two study groups, plotting the Δ value
between the mean index values in the two groups (e.g.
the Δ value for each individual reactivity, peptide by
peptide in ‘test group’ as compared to the ‘reference’
group. The entire set of differences can be compiled in
a 3D graphical representation).
All pre-processing and statistical analyses were per-
formed customizing open-source packages of Biocon-
ductor, R software [21,22]. In addition, to assess the
statistical significance of the differences in the trends of
recognition (defined as the sequence of the observations
in 100%, 90% and 80% in serum from children in each
group) with whooping cough group vs. all remaining
groups, as well as the DT (control) group vs. the
remaining groups, a Chi-square test for the goodness of
fit was used.
Epitope comparison with published data
In order to relate our results to the epitopes which have
been identified previously in the literature, we searched
the B-cell Immune Epitope Database [23] (IEDB) site
(http://www.immuneepitope.org/) and homologous se-
quences highlighted.
Results
Differential recognition of Bp epitopes in children with
whooping cough
Three thousand eighty five peptides remained in the ana-
lysis after quality control, i.e. after false positive, empty andlow intensity signal spots removal. Analysis of sera from
children with whooping cough showed that 367 (11.9%) of
3,085 peptides were commonly recognized in in 10/10
serum samples. 239 (7.7%) peptides were recognized in 10/
10 serum samples from subjects who received the DTPwc
vaccine, while 259 (8.4%), 105 (3.4%) and 179 (5.8%) pep-
tides were recognized in sera obtained from 10/10 children
receiving the DTPa5 vaccine, the DTPa2 vaccine or the DT
vaccine, respectively (without a diagnosis of whooping
cough). Figure 1 shows the number of peptides recognized
in serum from 10/10, 9/10 and 8/10 children in each
group [see for details Figure S2 (distribution of peptide
recognition for each group) in the online material]. The
trend of peptide epitope recognition was similar between
natural Bp infection and DPTwc (p = NS), while it was sta-
tistically different between serum recognition patterns
associated with whooping cough and the groups who re-
ceived the acellular vaccines (p < 0.05 vs. DTPa5, p < 0.001
vs. both DTPa2 and DT). Table 2 shows the frequency of
recognition per peptide species, their origin on the re-
spective Bp protein, stratified for the study groups.
Figure 2 shows the 3D representation of the “reactome”
in each group, this ‘landscape recognition pattern’ depicts
the qualitative appreciation of differences in antibody rec-
ognition patterns between different (vaccine) groups as a
function of the IgG signal strength to individual Bp epi-
topes. The IgG target recognition pattern induced by the
DTPwc and the DTPa5 vaccines were similar to the serum
pattern from children with whooping cough, while the
DTPa2 group showed a shape similar to the recognition
pattern detected in the DT group [see also Additional file 3
Video S1 (differences in B. pertussis recognition patterns)
in the online data supplement].
Different IgG reactome and exclusive recognition of Bp
epitopes in sera from infected children
Next, we visualized differences between the ‘reactome
patterns’. The Bp serum recognition pattern from individ-
uals with whooping cough and from the DTPa2 groups
showed a characteristic shape of IgG recognition curves
using the computed Δ value for mean indexes using the
DT group as a reference (Figure 3A and the Figure S3,
3D-plots recognition of the differential mean index value
in each study group, in the online supplementary mater-
ial). The 3D-plots visualize the differential mean index
value in the whooping cough (Figure 3A, left panel) and
DTPa2 (Figure 3A, right panel) groups as compared to
the reference, i.e. the mean index value in the DT (refer-
ence) group. The 3D plots help to visualize the overall
recognition pattern, based on serum IgG binding to indi-
vidual epitopes, yet it does not identify peptides that are
exclusively recognized in a (test) group. We show in
Figure 3B the exclusive recognition analysis (ERA) of sera
from children with whooping cough (Figure 3B, left
Figure 1 Number of peptides recognized in each study group in all (10 out of 10), 90% (9 out of 10) and 80% (8 out of 10) serum samples
obtained from children s in each test group. The trend of recognition (defined by the observations in the three points in each group) was similar
between natural infection and DPTwc (p = NS), while it was statistically different in the comparison between natural infection and the remaining
groups (p < 0.05 vs. DTPa5, p < 0.001 vs. both DTPa2 and DT).
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DT group. These peptides are exclusively recognized in
the respective test group at the indicated frequency (e.g.
10/10 serum samples) and never in serum from any indi-
vidual in the DT group (n = 10 individuals). 12 peptides
were strongly recognized in serum from at least 8 out 10Table 2 Recognition frequency of target peptides spotted on
target proteins
B. pertussis protein GENE Wh
Pertussis toxin subunit 1 precursor PtxS1 4
Pertussis toxin subunit 2 precursor PtxS2 3
Pertussis toxin subunit 3 precursor PtxS3 5
Pertussis toxin subunit 4 precursor PtxS4 2
Pertussis toxin subunit 5 precursor PtxS5 3
P.69A protein (pertactin) Prn 11
Filamentous hemagglutinin fhaB 27
Fim2 pilic subunit fim2 1
Serotype 3 fimbrial subunit precursor fim3 2
Tracheal colonization factor tcfA 19
Bifunctional hemolysin-adenylate cyclaseprecursor cyaA 61
Outer membrane porin protein precursor ompP 27
Outer membrane porin protein OmpQ ompQ 37
GTP-binding elongation factor bipA 26
Bordetella resistance to killing brkA 10
Vag8 protein (Autotransporter) vag8 44
Putative autotransporter bapC 69
The table shows the recognition frequency of target peptides spotted on the micro
cough: children who received the placebo and developed whooping cough; DTPwc
Pertussis 5 component vaccine; DTPa2: Diphtheria Tetanus Pertussis 2 component v
groups N = 10; none of the children in the vaccine groups, including DT, were diagnof the children developing whooping cough and never in
any serum samples from an children in the DT (control
group, see also Figure S4, i.e. the exclusive recognition
analysis (ERA) for peptides exclusively detected in each
of the study groups vs. serum from non vaccinated chil-
dren, in the supplementary material).the microarray slides, stratified per study group and by






3 6 2 4
10 11 5 14
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15 10 7 9
41 50 22 39
16 16 4 12
32 36 12 24
16 13 9 8
7 8 9 6
28 28 8 18
47 54 21 25
array slides, stratified per study group and by target proteins. Whooping
: Diphtheria Tetanus Pertussis whole cell vaccine; DTPa5: Diphtheria Tetanus
accine; DT: children who received only the Diphtheria Tetanus vaccine; all
osed with a condition related to B. pertussis infection.
Figure 2 3D-plots representing the mean index value reactivity in each individual study group. A) DTPwc: children who received the Diphtheria Tetanus
Pertussis whole cell vaccine; B) DTPa5: Diphtheria Tetanus Pertussis 5 components vaccine; C) DTPa2: i Diphtheria Tetanus Pertussis 2 components
vaccine; D) Whooping cough: children who received the placebo and developed natural infection; E) DT: children vaccinated the placebo, who did not
develop whooping cough. The proteins on the microarray are aligned the : 1 - P.69A protein (pertactin); 2 - Bordetella resistance to killing; 3 - Tracheal
colonization factor; 4 - Vag8 protein (Autotransporter); 5 - Pertussis toxin subunit 1 precursor; 6 - Pertussis toxin subunit 2 precursor; 7 - Pertussis toxin
subunit 3 precursor; 8 - Pertussis toxin subunit 4 precursor; 9 - Pertussis toxin subunit 5 precursor; 10 - Bifunctional hemolysin-adenylate cyclaseprecursor;
11 - Filamentous hemagglutinin; 12 - Fim2 pilic subunit; 13 - Serotype 3 fimbrial subunit precursor; 14 - Outer membrane porin protein precursor;
15 - Outer membrane porin protein OmpQ; 16 - GTP-binding elongation factor; 17 - putative autotransporter. The DTPwc and the DTPa5 vaccines were
similar to the pattern obtained from serum from children diagnosed wth whooping cough, while the DTPa2 group showed a shape similar to the IgG
recognition pattern detected in the DT group.
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topes (from Bp virulence proteins) could be identified in
10/10 serum samples from patients with whooping
cough; 2 peptides were derived from pertussis toxin
components (1 from PtxS4, and 1 from cyaA); 3 peptides
from adhesion proteins (2 from prn, and 1 from FHA);
and 1 peptide from the transporter protein ompP. In
serum samples from the DTPa2 group, 1 peptide was
derived from the tracheal colonization factor (tcfA) and
a different peptide epitope from the GTP-binding elong-
ation factor (bipA). The two peptides specifically recog-
nized in the DTPa2 group did not belong to the 2 proteins
used as vaccine components; the sequence of these 8
peptides is reported in Table 3. We performed then a
comparative 3D analysis of Bp epitope recognition inserum from children with whooping cough versus the con-
trol, i.e. the reference group who received DT (Figure 4),
to visualize which Bp proteins are predominantly recog-
nized in serum from Bp- infected children. Strong IgG epi-
tope target recognition could be observed to components
of filamentous hemagglutinin, yet comparatively relatively
weak IgG reactivity directed against the Vag8 protein and
a factor which confers resistance to killing.
Differential recognition of Bp epitopes identified by PAM
segregates Bp vaccines
The exclusive epitope recognition analysis yields peptide
targets that are unique for each test cohort. A different
kind of analysis, PAM, identifies epitopes that are both
always strongly recognized in the reference, and always
Figure. 3 Differential target epitope recognition in patients with whooping cough. Figure 3A: 3D-plots representing the differential mean index
value in the whooping cough (left panel) and DTPa2 (right panel) groups as compared to the reference the mean index value in the DT group.
Figure 3B: Inclusive/exclusive analysis of serum reactivity from children in the whooping cough (left panel) and DTPa2 (right panel) groups vs. the
DT (control) group. These peptides are exclusively recognized in the respective test group at the indicated frequency (e.g. 10/10 serum samples)
and never in serum from any individual in the DT group. 12 peptides were strongly recognized in serum from at least 8 out 10 of the children
developing whooping cough; 8 peptides were highly recognized in serum from at least 8 out of 10 infants in the DTPa2 group. No specific
pattern of recognition was detected by the inclusive/exclusive analysis in the other study groups. DTPa2: infants who received the Diphtheria
Tetanus Pertussis 2 components vaccine, DT: infants not vaccinated and who did tno developed whooping cough.
Table 3 Sequence of target epitopes exclusively recognized in serum from individuals either with the natural B. pertussis
infection or after DTPa2 vaccination
B. pertussis protein GENE B-cell epitope
Children with whooping cough
Pertussis toxin subunit 4 precursor PtxS4 CFGKDLKRPGSSPME
P.69A protein (pertactin) Prn LWYAESNALSKRLGE
P.69A protein (pertactin) Prn AVVHLQLATIRRGDA
Filamentous hemagglutinin fhaB FAADLRTVYAKQADQ
Bifunctional hemolysin-adenylate cyclaseprecursor cyaA HAANQAVDQAGIEKL
Outer membrane porin protein precursor ompP FGVNTFADGFKANSY
Children who received the the DTPa2 vaccine
Bifunctional hemolysin-adenylate cyclaseprecursor cyaA DQTVSGLEIGLDRGV
Tracheal colonization factor tcfA ASNGLRIKDDGTNSM
The Table shows the sequence of target epitopes specifically recognized in serum (10/10) children with whooping cough (n = 6 peptides) and in serum from
children who receivedthe Diphtheria, Tetanus, Pertussis acellular 2 components (DTPa2) vaccine (2 peptides). Peptide microarray slides containing unique Bp
peptides (n = 3,085 peptides) were processed and analyzed. We list here only peptides which were exclusively recognized in serum samples from individuals
either with the natural Bp infection or after DTPa2 vaccination and never recognized in any serum samples from individuals who received the placebo (i.e. DT ).
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Figure 4 3D-plots representing the differential mean index IgG
recognition value in serum from whooping cough group. The mean
index IgG value in the DT group was used as reference. This graph
highlights proteins with high (A and B: filamentous hemagglutinin, FHA)
and low (C: Bordetella resistance to killing, BrkA, Vag8 protein, Putative
autotransporter, BapC) mean index values. This ’ landscape analysis’ aids to
visualize the global recognition pattern of peptides recognized in serum
samples from each group, it also allows to appreciate clear differences
in the serum recognition pattern to Bp components in each test group.
Note the strong recognition of Bp components to filamentous
hemagglutinin, yet the relative decrease of antibody reactivities directed
against the Vag8 protein and a factor which confers resistance to killing.
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serum from each individual in the group. This allows
predicting whether a reactivity pattern is associated to a
certain defined endpoint (e.g. infection or vaccination,
vaccination versus placebo). Alternatively, this method
allows also comparing groups of individuals, i.e. individ-
uals who received different kinds of Bp vaccines.
Figure 5 shows the comparison of the vaccinated
groups, as well as the Bp-infected group along with the
group who received (DT) placebo. The peptide epitope
targets are only shown if they exhibited a constant re-
activity pattern for each of the 10 individuals in the test
groups. The DTPa2 group yielded 45, the DTPa5 100
and the whole cell vaccine 42 Bp targets that were differ-
entially recognized as compared to the placebo group.
Infection with Bordetella pertussis yielded 32 targets that
were differentially recognized as compared to the group
who received (DT) placebo. The identity of these targets
and location within each target molecule is provided in
the online Additional file 2: Table S2 (Differential epitope
recognition analysis). The comparison between the vacci-
nated groups with the 10 individual who experiencednatural infection resulted in 29 targets for the DTPa2, 43
targets for the DTPa5 and 42 targets for the group who
received the whole cell vaccine (Figure 6). As expected,
the comparison between the placebo and the infected
group results also in 32 Bp targets that would segregate
infected versus non- Bp infected individuals. The detailed
listing of the targets is provided in the Additional file 2:
Table S2 (Differential epitope recognition analysis).Peptide microarray analysis identifies previously
described B-cell epitopes
Finally, we examined if already published Bp epitopes
were captured by the peptide microarray matrix: sixty-
five B. pertussis B-cell epitopes were retrieved from the
IEDB (listed in the Additional file 2: Table S3, B-cell epi-
topes identified via online data repositories, in the online
supplementary material, see also Figure S5, i.e. Plots of
previously reported epitopes and epitopes using the
peptide microarray approach, in the online data supple-
ment), showing that the platform utilized in this report
picks up already described B-cell epitopes. We identified
Bp target peptides that were frequently recognized;
these target peptides exhibited a variant amino acid se-
quence which occurs in natural Bp clinical isolates – the
non-variant peptide epitopes were not recognized (see
Additional file 2: Table S3, previously described epitopes,
and S4, commonly recognized epitopes in serum from the
respective patient groups, in the online data supplement).Discussion
Primary prevention remains the main intervention to
limit pertussis occurrence and new transmission. The
protective effect mediated by the Bp vaccine(s) appeared
to vanish over time [3] and emergence of Bp strains carry-
ing mutations of virulence factors has been reported [9]
Our study explored the immune response against Bp
induced by natural infection and 3 different vaccines in
children enrolled in a clinical trial conducted in Sweden
[12]: this trial showed that acellular vaccines, in particular
DTPa5, ensured the best ratio between protection from
whooping cough and acceptable rates of side effects.
We have been able to i) identify a high number of B-
cell epitopes that have been described in the literature
and the Bp epitope database with the peptide microarray
technology described in this report (supplementary
Table S5), ii) show robust differences between different
vaccines concerning epitope recognition patterns (see
Figures 5 and 6), and iii) picked up differences in IgG
mutant Bp epitopes, i.e. that not the wildtype, yet the
naturally occurring variant Bp epitope was recognized
(Supplementary Figure S5). These results suggest that
peptide microarrays provide a platform to visualize quanti-
tative and qualitative differences in humoral recognition
Figure 5 PAM analysis of strongly versus weakly recognized Bp target epitopes segregates vaccination with different vaccines compared to healthy
controls (who received the DT adjuvant and tested sero-negative for a previous Bp infection). Epitopes are recognized in serum from 10/10 individuals
in each group, the number of targets that segregates each group is listed. The colors are based on the fluorescence intensity of the peptide microarray
results. Red: strong recognition and green: weak recognition. The identity of each target peptide is listed in the Additional file 2: Table S2.
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genetic changes in Bp have been reported [24-28].
Serum from children with whooping cough displayed
the broadest Bp epitope antibody recognition, with a
certain number of peptides exclusively recognized in this
group. Only serum analysis from individuals vaccinated
with DTPwc showed a similar trend concerning the
number of recognized Bp peptides, consistent with the
fact that all the components of the bacterial wall are
present in this vaccine preparation. The DTPa5 as well
as the DTPa2 vaccine induced a significantly different
humoral recognition pattern. The DTPa2 vaccine ap-
peared to boost pre-existing Bp-reactive antibody re-
sponses as compared to the induction and expansion of
new antibody reactivity pattern directed to new Bp tar-
get antigens.. This is reflected in stronger recognition of
the proteins Bordetella resistance to killing (BrkA), Vag8
protein, Putative autotransporter (BapC). Conversely,
humoral recognition of the filamentous hemagglutinin
(FHA) appears to be induced by vaccination with the
DTPwc vaccine as well as after natural infection with Bp.The immune responses induced by Bp in the course of
whooping cough after resolution is long-lasting and more
protracted as compared to the immune response in-
duced by vaccines; it may offer new potential targets to
improve vaccine design for pertussis once the nature of
the antibody reactivity mediating immune protection
will be deciphered. The DTPa2 vaccine has a very good
safety profile, yet its effect has been questioned in the
past particularly in terms of protection and its duration
[12]. This could, in part, be explained by the fact that
the DTPa2 vaccine acts by boosting a pre-existing ‘nat-
ural’ Bp recognition matrix, as compared to other vac-
cines which rather induced a shift in serum Bp epitope
recognition patterns. Both DTPwc and DTPa5 showed a
reactome similar to the Bp natural infection; future stud-
ies may address whether this would be related to in-
creased protection induced by these vaccines compared
to the DTPa2 [12].
There are at least four different, not mutually exclusive
explanations concerning the spectrum of Bp target rec-
ognition induced by different vaccines: i) Vaccines could
Figure 6 PAM analysis of strongly versus weakly recognized Bp target epitopes segregates vaccination with different vaccines compared to
individuals with Pertussis. Epitopes are recognized in 10/10 serum samples in each group, the number of targets that segregates each group is
listed. The colors are based on the fluorescence intensity of the peptide microarray results. Red: strong recognition and green: weak recognition.
The identity of each target peptide is listed in the supplementary online material Table S2.
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occurring and Bp specific antibodies directed against
Bordetella spp, eliciting pre-existing humoral immune
responses directed against Bp epitopes. This is consistent
with the concept that ‘natural antibodies’ are a funda-
mental part of the immune system and play a crucial
role in modulating the recognition (and response) to self
and ‘non-self ’ infectious antigens [29,30] ii) Children with-
out Bp vaccination experience most likely the full-blown
disease with the typical whooping cough presentation, yet
some (non-vaccinated) individuals appear to experience
limited disease, suggesting that ‘abortive’ cases or even im-
mune protection may occur in the absence of vaccination
[31,32]. Therefore, silent infection or colonization with
other Bordetella species (which may also express certain
virulence factors, e.g. B. parapertussis and B. bronchisep-
tica,, as well as B. trematum and B. holmesii) [33,34] could
be responsible in the modulation of the immunological
recognition matrix directed against Bp.
Most of the serum immune responses in the groups of
our study were shared among the individuals in eachgroup (with up to 11.9% of Bp peptides recognized in
sera from 10/10 infants with whooping cough), yet we
identified also ‘private’ humoral responses unique for
each individuals (see Figure S2 in the online data supple-
ment); iii) Potentially cross-reactive antibodies which
target closely related hemagglutinin or fimbriae from
other bacterial species may be responsible for different
efficacy of the vaccines iv) Vaccination leads not only to
epitope-specific immune responses directed against
targets contained in the vaccine, yet to other molecular
targets as well (epitope spreading). This concept is
appreciated in other areas of medicine and contributes to
clinical efficacy of some vaccines. For instance, antigen-
spreading mediates vaccination-induced regression in hu-
man melanoma [35] and the impact of different (vaccine)
adjutants on the antibody repertoire to target protective
epitopes is appreciated in the development of humoral and
cellular immune responses against influenza A [36,37].
If the human proteome is scanned as 5mer peptides,
then up to 90% of the viral proteome may show similar-
ity to the human proteome [38]. This information is
Valentini et al. BMC Immunology  (2015) 16:40 Page 11 of 12more easily accessible using peptide microarrays, since
IgG recognition patterns are mapped using defined pep-
tide targets that can be tested for amino acid composition
similarities with related or unrelated protein targets.
We show here that not only the antibody titers directed
against specific Bp targets, yet also the detailed recognition
focus of vaccine components was different, even if the vac-
cines contained the same molecular components, support-
ing the notion that Bp vaccine composition impacts on the
quality of antibody response [25,39-41].
Peptide-microarray-guided analysis may also help to
decipher the phenomenon of ‘epitope suppression’ [42]
which has recently gained interest in Bp vaccine evalu-
ation. Individuals primed with a Bp (one dose) whole cell
vaccine exhibited decreased pertussis attack rates as
compared to individuals primed with acellular vaccines
[43,44]: differential target epitope focus associated with
different vaccine formulation was evident in the PAM-
analysis reported in the current study (see Figures 5 and
6, the detailed target epitope focus analysis is provided
in the Additional file 2: Table S2).
Conclusion
Microarray analysis offered for the first time a compre-
hensive characterization of the immune response to Bp
after natural infection in comparison to 3 vaccines. The
report shows the potential of the high-content peptide
microarray technique in infectious diseases, detecting
epitopes by far more numerous and likely more immuno-
genic compared to the ones already reported in electronic
databases. It also offers a new possibility to objectively
decipher immune reactivity in clinically well-defined test
groups undergoing vaccination strategies and allows to
test for batch-to-batch consistency. Target recognition
patterns in serum from individuals who experienced infec-
tion with Bp (and enjoyed protection for a longer period
of time) could guide the development of Bp vaccines.
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